Daniel Arizpe, Alexander J Gallan, Adam M Kase, Murli Krishna, Surendra Dasari, Burak Tekin, Rafael E Jimenez, Lori A Erickson, John C Cheville, Sounak Gupta
{"title":"alk -重排肾肿瘤:一个机构队列的最新进展。","authors":"Daniel Arizpe, Alexander J Gallan, Adam M Kase, Murli Krishna, Surendra Dasari, Burak Tekin, Rafael E Jimenez, Lori A Erickson, John C Cheville, Sounak Gupta","doi":"10.1007/s00428-025-04292-2","DOIUrl":null,"url":null,"abstract":"<p><p>Anaplastic lymphoma kinase-rearranged renal cell carcinoma (ALK-RCC) is a rare and recently recognized molecular subtype of RCC defined by ALK gene fusions. We describe five ALK-RCC and one likely ALK-rearranged epithelioid mesenchymal neoplasm from both pediatric and adult patients. Tumors exhibited diverse morphologic features, including papillary, mucinous, and cribriform patterns. ALK expression was confirmed in all cases by immunohistochemistry. Molecular profiling revealed several fusion partners including ARNT, EML4, NUMA1, TPM3, and VCL. A single patient with a VCL::ALK gene rearrangement had sickle cell trait. Novel gene rearrangements in RCC include NUMA1::ALK and ARNT::ALK. Metastatic disease was documented in three patients, and two died of disease. This series underscores the morphological heterogeneity of ALK-RCC (including frequent papillary and mucinous features), is informative of novel fusion partners such as NUMA1 and ARNT, further highlights the association of the VCL::ALK fusion with sickle cell trait, and is informative of the natural history of disease in a subset of patients.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ALK-Rearranged renal neoplasms: update on an institutional cohort.\",\"authors\":\"Daniel Arizpe, Alexander J Gallan, Adam M Kase, Murli Krishna, Surendra Dasari, Burak Tekin, Rafael E Jimenez, Lori A Erickson, John C Cheville, Sounak Gupta\",\"doi\":\"10.1007/s00428-025-04292-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Anaplastic lymphoma kinase-rearranged renal cell carcinoma (ALK-RCC) is a rare and recently recognized molecular subtype of RCC defined by ALK gene fusions. We describe five ALK-RCC and one likely ALK-rearranged epithelioid mesenchymal neoplasm from both pediatric and adult patients. Tumors exhibited diverse morphologic features, including papillary, mucinous, and cribriform patterns. ALK expression was confirmed in all cases by immunohistochemistry. Molecular profiling revealed several fusion partners including ARNT, EML4, NUMA1, TPM3, and VCL. A single patient with a VCL::ALK gene rearrangement had sickle cell trait. Novel gene rearrangements in RCC include NUMA1::ALK and ARNT::ALK. Metastatic disease was documented in three patients, and two died of disease. This series underscores the morphological heterogeneity of ALK-RCC (including frequent papillary and mucinous features), is informative of novel fusion partners such as NUMA1 and ARNT, further highlights the association of the VCL::ALK fusion with sickle cell trait, and is informative of the natural history of disease in a subset of patients.</p>\",\"PeriodicalId\":23514,\"journal\":{\"name\":\"Virchows Archiv\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Virchows Archiv\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00428-025-04292-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virchows Archiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00428-025-04292-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
ALK-Rearranged renal neoplasms: update on an institutional cohort.
Anaplastic lymphoma kinase-rearranged renal cell carcinoma (ALK-RCC) is a rare and recently recognized molecular subtype of RCC defined by ALK gene fusions. We describe five ALK-RCC and one likely ALK-rearranged epithelioid mesenchymal neoplasm from both pediatric and adult patients. Tumors exhibited diverse morphologic features, including papillary, mucinous, and cribriform patterns. ALK expression was confirmed in all cases by immunohistochemistry. Molecular profiling revealed several fusion partners including ARNT, EML4, NUMA1, TPM3, and VCL. A single patient with a VCL::ALK gene rearrangement had sickle cell trait. Novel gene rearrangements in RCC include NUMA1::ALK and ARNT::ALK. Metastatic disease was documented in three patients, and two died of disease. This series underscores the morphological heterogeneity of ALK-RCC (including frequent papillary and mucinous features), is informative of novel fusion partners such as NUMA1 and ARNT, further highlights the association of the VCL::ALK fusion with sickle cell trait, and is informative of the natural history of disease in a subset of patients.
期刊介绍:
Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.